- Home
- RYTM vs APGE Comparison
RYTM vs APGE Comparison
Compare RYTM & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- APGE
- Stock Information
- Founded
- RYTM 2008
- APGE 2022
- Country
- RYTM United States
- APGE United States
- Employees
- RYTM N/A
- APGE N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYTM Health Care
- APGE Health Care
- Exchange
- RYTM Nasdaq
- APGE Nasdaq
- Market Cap
- RYTM 3.1B
- APGE 3.0B
- IPO Year
- RYTM 2017
- APGE 2023
- Fundamental
- Price
- RYTM $57.07
- APGE $38.75
- Analyst Decision
- RYTM Strong Buy
- APGE Strong Buy
- Analyst Count
- RYTM 10
- APGE 5
- Target Price
- RYTM $66.90
- APGE $83.50
- AVG Volume (30 Days)
- RYTM 549.1K
- APGE 470.7K
- Earning Date
- RYTM 02-20-2025
- APGE 03-04-2025
- Dividend Yield
- RYTM N/A
- APGE N/A
- EPS Growth
- RYTM N/A
- APGE N/A
- EPS
- RYTM N/A
- APGE N/A
- Revenue
- RYTM $112,530,000.00
- APGE N/A
- Revenue This Year
- RYTM $63.77
- APGE N/A
- Revenue Next Year
- RYTM $44.91
- APGE N/A
- P/E Ratio
- RYTM N/A
- APGE N/A
- Revenue Growth
- RYTM 81.55
- APGE N/A
- 52 Week Low
- RYTM $35.17
- APGE $32.78
- 52 Week High
- RYTM $68.58
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- RYTM 52.43
- APGE 41.17
- Support Level
- RYTM $52.71
- APGE $36.48
- Resistance Level
- RYTM $60.12
- APGE $42.98
- Average True Range (ATR)
- RYTM 2.11
- APGE 2.78
- MACD
- RYTM -0.00
- APGE -0.60
- Stochastic Oscillator
- RYTM 58.93
- APGE 26.56
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.